Luye Pharma Group Ltd (02186.HK) saw its stock price soar by 5.69% in Friday's pre-market trading session, following the release of its impressive half-year financial results for 2025. The pharmaceutical company's strong performance across key financial metrics appears to have boosted investor confidence.

According to the financial report, Luye Pharma achieved a net income of RMB 357.4 million for the first half of 2025. The company's revenue reached RMB 3,181.1 million, with a gross profit of RMB 2,157.6 million. Notably, Luye Pharma maintained a robust gross margin of 67.8%, indicating strong profitability in its operations.

The positive market reaction suggests that investors are optimistic about Luye Pharma's financial health and growth prospects. The company's ability to maintain a high gross margin in the competitive pharmaceutical industry is particularly noteworthy. As the market digests these results, analysts may be looking for signs of sustainable growth and potential expansion in Luye Pharma's product pipeline or market reach.